Sana Biotechnology, Inc. $SANA Shares Sold by Rafferty Asset Management LLC

Key Points

• Rafferty Asset Management LLC reduced its stake in Sana Biotechnology by 37.8%, now holding 195,135 shares valued at $328,000 after selling 118,716 shares in the first quarter.
• Several institutional investors, including Tower Research Capital, increased their holdings, with Tower's stake rising by 229.9% in the fourth quarter.
• Analysts have varying target prices for Sana Biotechnology, with a consensus average target price of $8.00 and a "market outperform" rating from JMP Securities.

Rafferty Asset Management LLC lowered its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 37.8% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 195,135 shares of the company's stock after selling 118,716 shares during the period. Rafferty Asset Management LLC owned approximately 0.09% of Sana Biotechnology worth $328,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in SANA. Wells Fargo & Company MN grew its holdings in shares of Sana Biotechnology by 51.0% in the fourth quarter. Wells Fargo & Company MN now owns 62,021 shares of the company's stock valued at $101,000 after purchasing an additional 20,950 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Sana Biotechnology by 44.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock worth $2,538,000 after acquiring an additional 478,596 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock worth $25,000 after acquiring an additional 10,548 shares during the last quarter. Hsbc Holdings PLC lifted its position in shares of Sana Biotechnology by 140.1% during the 4th quarter. Hsbc Holdings PLC now owns 32,704 shares of the company's stock worth $53,000 after buying an additional 19,084 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Sana Biotechnology by 5.3% during the 4th quarter. Northern Trust Corp now owns 1,188,346 shares of the company's stock worth $1,937,000 after buying an additional 60,004 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Trading Down 0.7%

NASDAQ:SANA traded down $0.02 during trading hours on Friday, hitting $2.96. The stock had a trading volume of 3,612,816 shares, compared to its average volume of 4,792,999. Sana Biotechnology, Inc. has a 1-year low of $1.26 and a 1-year high of $7.30. The business has a 50 day simple moving average of $3.71 and a two-hundred day simple moving average of $2.70. The company has a market cap of $703.92 million, a PE ratio of -2.79 and a beta of 1.88.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. Research analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Morgan Stanley began coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 price target for the company. JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $8.00.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.